Vertex Retains all North American Rights Janssen Obtains Exclusive Rights in Europe and Other Regions Vertex to Receive $165 Million Upfront; Tiered Royalty Averaging mid-20 Percent Range Based on Successful Commercialization New Brunswick, NJ and Cambridge, MA, June 30, 2006 -- Vertex
Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals
- VX-950 Global Phase 2b Clinical Development Plan On Track -<br>
- Collaboration with Janssen Pharmaceutica, a Johnson & Johnson Company,
Adds Important Strengths<br>
and Development Capabilities for VX-950 -
Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011 Cambridge, MA, August 3, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that three holders of its 5.75% Convertible Senior
Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens Toronto, Canada, August 13, 2006 -- Updated treatment guidelines issued today by the International AIDS Society-USA (IAS-USA) now include the HIV protease inhibitor
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 19th Annual Healthcare Conference Cambridge, MA, September 8, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Bear Stearns 19th Annual Healthcare Conference.
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, September 11, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 8,000,000 shares of its newly issued common stock in an underwritten public offering.
Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, September 14, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common stock at a price of $33.00 per share.
Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, September 20, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common stock. The gross proceeds, before commissions and
Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study San Francisco, CA, September 28, 2006 -- Data presented today show low rates of virologic failure and antiviral drug resistance with the HIV protease inhibitor LEXIVA boosted with
Vertex Pharmaceuticals Added to NASDAQ-100 Index Cambridge, MA, December 11, 2006 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Company will be added to the NASDAQ-100 Index(R), effective with the market open on Monday, December 18, 2006.
Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950) Cambridge, MA, December 13, 2006 –– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a planned
Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference PROVE program to prepare for Phase 3 initiation of telaprevir (VX-950) Expanding clinical development into important HCV sub-populations Vertex building foundation for commercialization of
--PROVE program to prepare for Phase 3 initiation of telaprevir (VX-950)--<br><br>
-- Expanding clinical development into important HCV sub-populations --<br><br>
-- Vertex building foundation for commercialization of telaprevir --
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Wachovia Securities Small and Mid-Cap Healthcare Conference Cambridge, MA, January 24, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Wachovia
Vertex Pharmaceuticals Reports 2006 Financial Results Cambridge, MA, February 1, 2007 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ended December 31, 2006. “2006 was characterized by significant progress across our
Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011 Cambridge, MA, February 2, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 5, 2007 it will redeem the outstanding $59.6 million aggregate principal amount of
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences Cambridge, MA, February 5, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotechnology
CAMBRIDGE, Mass., Feb 22, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Bear Stearns Ninth Annual London Healthcare Conference on Tuesday, February 27, 2007 at 11:20 a.m. GMT (6:20 a.m. EST).
CAMBRIDGE, Mass., Mar 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in connection with the previously announced redemption of its 5.75% Convertible Senior Subordinated Notes due 2011, holders of all of the outstanding notes converted their notes
CAMBRIDGE, Mass., Mar 07, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Cowen and Company 27th Annual Health Care Conference on March 13, 2007 at 8:45 a.m. EDT and at the Citigroup Small & Mid-Cap Conference on March 14, 2007 at
CAMBRIDGE, Mass., Apr 26, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2007 at 2:15 p.m. EDT and at Deutsche Bank's 32nd Annual Health Care Conference on May 3, 2007
CAMBRIDGE, Mass., Apr 30, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2007. "In 2007, a major goal for Vertex is to build the product profile of the investigational hepatitis C protease
CAMBRIDGE, Mass., May 17, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentation at Citigroup's 2007 Global Healthcare Conference on May 23, 2007 at 4:00 p.m. EDT. The presentation will be webcast live and may be accessed from the 'Events Calendar'
CAMBRIDGE, Mass., May 31, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2007 Annual Meeting of Stockholders. At the meeting, stockholders re-elected Joshua Boger, Ph.D., Charles A. Sanders, M.D., and Elaine S.
CAMBRIDGE, Mass., Jun 01, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Bear Stearns Biotech Confab on Thursday, June 7th at 7:50 a.m. EDT and at the Goldman Sachs 28th Annual Global Healthcare Conference on Wednesday, June 13th at
-- More than 1000 patients have now been enrolled in Phase 2b PROVE trials -- More than 350 patients have completed 12 weeks of telaprevir dosing in PROVE trials -- Interim results from PROVE 2 consistent with findings from PROVE 1
CAMBRIDGE, Mass., Jun 29, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Kurt C. Graves as Executive Vice President, Chief Commercial Officer and Head, Strategic Development. Vertex also announced today that Amit K.
CAMBRIDGE, Mass., Jul 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2007 financial results on Tuesday, July 24, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
CAMBRIDGE, Mass., Jul 24, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2007, and the Company provided a pipeline update. "Vertex achieved its major development pipeline milestones in the first
CAMBRIDGE, Mass., Sep 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bear Stearns 20th Annual Healthcare Conference on Monday, September 10th at 3:00 p.m. EDT.
CAMBRIDGE, Mass., Sep 14, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference on Tuesday, September 18th at 1:00 p.m. GMT (8:00 a.m.
-- Conference Presentations to Include Data from Two Randomized, Controlled Phase 2 Clinical Studies of Investigational HCV Protease Inhibitor Telaprevir --
CAMBRIDGE, Mass., Oct 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2007 financial results on Monday, October 29, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update Important telaprevir data to be presented at AASLD Additional compounds for HCV and Cystic Fibrosis scheduled to enter development Cambridge, MA, October 29, 2007 Vertex
Two Large Phase 2 Trials of Telaprevir, an Investigational Hepatitis C Protease Inhibitor, Dosed in Combination with Pegylated Interferon and Ribavirin Show SVR Rates of 61% and 65% Initial Rapid Viral Decline Appears Important to Achieve SVR Safety Profile Consistent with Prior Interim Analyses
Cambridge, MA, November 5, 2007 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the 9th Annual MASS Opportunities Investment Conference on Thursday, November 8, 2007 at 2:45 p.m.
-- Companies continue broad program to develop investigational Aurora kinase inhibitors as novel treatments for a range of cancers -- -- Merck to initiate clinical development of VX-689 --
CAMBRIDGE, Mass., Nov 21, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the CIBC World Markets 3rd Annual Mid & Small Cap 'Best Ideas' Conference on Wednesday, November 28, 2007 at 8:45 a.m. EST.
CAMBRIDGE, Mass., Jan 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008 at 2:00 p.m. PST (5:00 p.m. EST).
- Formal European scientific advice obtained for telaprevir development program - - Meeting scheduled with FDA for January 2008 on Phase 3 trial design and recent data - - Next-generation HCV protease inhibitor and two investigational compounds for cystic fibrosis in clinical development -
-- Primary Phase 3 trial will focus on studying 24-week telaprevir-based regimens -- Vertex plans concurrent second study to support registration -- Final data from both trials anticipated in mid- 2010
